Invega Sustenna injection care in NYC

Nao Medical can coordinate psychiatric injection care with your prescribing psychiatrist. Share the current order, exact medicine, last dose date and treatment history through the confirmed clinical intake process. The clinicians review product-specific initiation or restart requirements and arrange medication delivery, administration and follow-up. Keep your existing treatment plan until the next appointment is agreed.

Invega Sustenna is a monthly paliperidone palmitate injection for adults with schizophrenia. It is also approved for schizoaffective disorder in adults, either alone or alongside a mood stabilizer or antidepressant. It has a specific two-injection initiation sequence followed by monthly maintenance. The one-month, three-month and six-month Invega injections are separate products with different eligibility and restart rules.

Before a first paliperidone injection, establish oral paliperidone or risperidone tolerability when it is unknown. Kidney function affects dosing. Sustenna is not recommended when creatinine clearance is below 50 mL/min, and mild impairment needs lower doses. The clinician also reviews heart rhythm risk, interactions, pregnancy, movement symptoms and previous response.

Bring oral and injection records, including any recent hospital doses. Discuss voices, suspicious thoughts, mood symptoms, sleep, concentration and daily function. Let the prescriber know which adverse effects matter most to you.

Usual adult initiation uses 234 mg in the shoulder muscle on day one and 156 mg there one week later. Kidney function can change whether treatment is appropriate and which regimen is used. This regimen is designed to reach concentrations without oral supplementation. Your prescriber must choose the appropriate plan.

The first maintenance injection is five weeks after the first injection. Later maintenance injections can use the shoulder or buttock muscle. Record the next due date and arrange continued psychiatric and physical-health review.

Call promptly if day-eight initiation or a monthly maintenance appointment is missed. During maintenance, a gap of more than six weeks may require two injections one week apart, while more than six months generally requires restarting initiation. Kidney function and the previous dose still matter. Do not use leftover risperidone or paliperidone tablets to make your own bridge.

Before a first paliperidone injection, establish oral paliperidone or risperidone tolerability when it is unknown. Kidney function affects dosing. Sustenna is not recommended when creatinine clearance is below 50 mL/min, and mild impairment needs lower doses. The clinician also reviews heart rhythm risk, interactions, pregnancy, movement symptoms and previous response.

A switch needs the responsible psychiatrist's documented plan, not just an administration appointment. Review the exact current product, strength, last dose, response and tolerability. The new injection has its own indication, prior-treatment, loading or oral-coverage rules. Ask whether Nao provides the prescribing evaluation or accepts an outside order, and confirm delivery, the administering site and follow-up before changing treatment. Do not stop or convert medicines yourself.

Continuing antipsychotic care reviews symptoms, daily function, injection dates, movement symptoms, sedation, falls, weight, blood pressure and medicine-specific blood tests. Blood sugar/lipids, prolactin or heart-rhythm assessment may be relevant depending on the product and history. Ask the psychiatrist which tests are due and who reviews them. An administration-only visit does not replace that care. Report new involuntary movements, marked restlessness, fainting or troublesome injection-site changes promptly.

The reviewed current US prescribing information for Invega Sustenna does not specify a restricted REMS administration/distribution program. That does not remove the medicine’s prescribing, administration, initiation or monitoring requirements. Confirm the exact product and current FDA status with the treating clinician and dispensing service; a manufacturer access program is not itself an FDA REMS.

Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.

Paliperidone can raise prolactin. Report changes in sexual function, periods, breast enlargement or milk production so the clinician can review symptoms and testing. Other causes may also need assessment.

Paliperidone continues to release after a Sustenna injection. The label reports a median apparent half-life of 25 to 49 days across the studied single-dose range. Drug levels fall gradually, so medicine may remain for months after the final injection. The monthly schedule is not a complete-clearance date. Kidney function, the dose and repeated treatment can affect the review of side effects or a switch. Give the clinician the exact last dose and date.

There is no single duration for all side effects. The injection keeps releasing paliperidone, so withholding the next dose will not remove medicine already given. Sleepiness or dizziness, movement symptoms, metabolic changes and prolactin-related effects need different assessments. Contact the prescriber about troublesome or persistent symptoms. Severe breathing difficulty, fainting, or high fever with muscle stiffness and confusion needs emergency assessment. Do not wait for the drug to clear before seeking help.

There is no single out-of-pocket amount for every patient. A new Sustenna start usually involves two initiation injections before monthly maintenance. Ask for a quote that separates medication, each administration, psychiatric visits and monitoring. Your plan may apply authorization, deductible, coinsurance or a required pharmacy. Ask which drug benefit will be billed and whether manufacturer assistance applies to your insurance type. Confirm the amount before treatment; a general office-visit benefit does not settle the injection bill.